Daniel Lang - 22 Nov 2021 Form 3 Insider Report for Athenex, Inc.

Role
Pres Cell Therapy, VP Corp Dev
Signature
/s/Steven Adams, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
22 Nov 2021
Net transactions value
$0
Form type
3
Filing time
01 Dec 2021, 16:07:56 UTC
Next filing
21 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ATNX Common Stock 73,413 22 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ATNX Stock Option (Right to Buy) 22 Nov 2021 Common Stock 40,000 $10.25 Direct F2
holding ATNX Stock Option (Right to Buy) 22 Nov 2021 Common Stock 50,000 $2.77 Direct F3
holding ATNX Restricted Stock Units 22 Nov 2021 Common Stock 50,000 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 30,000 shares subject to a restricted stock award vesting in four equal installments beginning on August 26, 2020.
F2 This option vests in four equal annual installments beginning on August 27, 2021.
F3 This option vests in four equal annual installments beginning on September 16, 2022.
F4 The restricted stock units vest in four equal annual installments beginning on September 16, 2022.
F5 Each restricted stock unit represents a contingent right to receive one share of stock.